Big pharma and the problem of disease inflation

International Journal of Health Services

Volumn 44, Issue 2, 2014, Pages 307-322

  Gabriel, Joseph M ^a   Goldberg, Daniel S ^b  

^a FLORIDA STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

^b EAST CAROLINA UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CORPORATE STRATEGY; CORROSION; DISEASE PREVALENCE; MARKET SYSTEM; MEDICAL GEOGRAPHY; PHARMACEUTICAL INDUSTRY;

ARTICLE; CLINICAL TRIAL (TOPIC); DRUG INDUSTRY; ETHICS; FORECASTING; FRAUD; HUMAN; MARKETING; MEDICAL ETHICS; MEDICALIZATION; OFF LABEL DRUG USE; PUBLIC HEALTH; UNITED STATES;

CLINICAL TRIALS AS TOPIC; DRUG INDUSTRY; ETHICS, MEDICAL; ETHICS, PHARMACY; FORECASTING; FRAUD; HUMANS; MARKETING; MEDICALIZATION; OFF-LABEL USE; PUBLIC HEALTH; UNITED STATES;

EID: 84899577829     PISSN: 00207314     EISSN: 15414469     Source Type: Journal    
DOI: 10.2190/HS.44.2.h     Document Type: Article

References (53)

1. U.S. Department of Justice. GlaxoSmithKline to plead guilty and pay $3 billion to resolve fraud allegations and failure to report safety data. http://www.justice.gov/opa/pr/2012/July/12-civ-842.html.
2. Thomas, K., and Schmidt, M. S. Glaxo agrees to pay $3 billion in fraud settlement. The New York Times, July 2, 2012.
3. U.S. Government. U.S.C. 21 301-97.
4. Nemeroff, C. B., et al. Impact of publicity concerning pediatric suicidality data on physician practice patterns in the United States. Arch. Gen. Psychiatry 64:466-472, 2007.
5. Lee, E., et al. Off-label prescribing patterns of antidepressants in children and adolescents. Pharmacoepidemiol. Drug Saf. 21:137-144, 2012.
6. Sismondo, S. Ghost management: How much of the medical literature is shaped behind the scenes by the pharmaceutical industry PLoS Med. 4:e286, 2007.
7. Lacasse J. R., et al. Knowledge of undisclosed corporate authorship (ghostwriting) reduces the perceived credibility of antidepressant research: A randomized vignette study with experienced nurses. BMC Res. Notes 4:27, 2011.
8. Stern, S., and Lemmens, T. Legal remedies for medical ghostwriting: Imposing fraud liability on guest authors of ghostwritten articles. PLoS Med. 8(8):e1001070, 2011.
9. Sismondo, S. Ghosts in the machine: Publication planning in the medical sciences. Soc. Stud. Sci. 39:171-198, 2009.
10. Lacasse, J. R., and Leo, J. Ghostwriting at elite academic medical centers in the United States. PLOS Med. 7(2):e1000230, 2010.
11. Rodwin, M. A. Rooting out institutional corruption to manage inappropriate off-label drug use. J. Law Med. Ethics 41:654-664, 2013.
12. Herper, M. A former pharma ghost writer speaks out. www.forbes.com, August 10, 2011.
13. Brody, H. T. Hooked: Ethics, the Medical Profession, and the Pharmaceutical Industry. Rowman & Littlefield, Hagerstown, 2007.
14. Elliot, C. White Coat, Black Hat: Adventures on the Dark Side of Medicine. Beacon Press, Boston, 2010.
15. Eaton, L. Medical editors issue guidance on ghost writing. BMJ 330:988, 2005.
16. Epstein, S. Impure Science: AIDS, Activism, and the Politics of Knowledge. University of California, Berkeley, 1998.
17. Wailoo, K. Drawing Blood: Technology and Disease Identity in Twentieth-Century America. Johns Hopkins University, Baltimore, 2009.
18. Rose, N. The Politics of Life Itself: Biomedicine, Power, and Subjectivity in the Twenty-First Century. Princeton University, Princeton, 2006.
19. Greene, J. Prescribing by Numbers: Drugs and the Definition of Disease. Johns Hopkins University, Baltimore, 2007.
20. Illich, I. Medical Nemesis: The Expropriation of Health. Pantheon Books, New York, 1976.
21. Moynihan, R., and Henry, D. The fight against disease mongering: Generating knowledge for action. PLoS Med. 3(4):e191, 2006.
22. Lexchin, J. Bigger and better: How Pfizer redefined erectile dysfunction. PLoS Med. 3(4):e132, 2006.
23. Healy, D. The latest mania: Selling bipolar disorder. PLoS Med. 3(4):e185, 2006.
24. Applbaum, K. Pharmaceutical marketing and the invention of the medical consumer. PLoS Med. 3(4):e189, 2006.
25. Payer, L. Disease-Mongers: How Doctors, Drug Companies, and Insurers are Making You Feel Sick. John Wiley & Sons, New York, 1994.
26. DeGrandpre, R. J. Ritalin Nation: Rapid-Fire Culture and the Transformation of Human Consciousness. W. W. Norton, New York, 2000.
27. Williams, S. J., Gabe, J., and Davis, P. Pharmaceuticals and Society: Critical Discourses and Debates. Wiley-Blackwell, New York, 2009.
28. Moynihan, R., and Cassels, A. Selling Sickness: How the Worlds Biggest Pharmaceutical Companies are Turning Us All Into Patients. Nation Books, New York, 2006.
29. Mosterd, A., et al. Trends in the prevalence of hypertension, antihypertensive therapy, and left ventricular hypertrophy from 1950 to 1989. N. Engl. J. Med. 340: 1221-1227, 1999.
30. Williams, S. J., et al. Waking up to sleepiness: Modafinil, the media and the pharmaceuticalisation of everyday/night life. Sociol. Health Illn. 30:839-855, 2008.
31. Horowitz, A., and Wakefield, J. The Loss of Sadness: How Psychiatry Transformed Normal Sorrow into Depressive Disorder. Oxford, New York, 2007.
32. Brody, H., and Light, D. W. The inverse benefit law: How drug marketing undermines patient safety and public health. Am. J. Pub. Health 101:399-404, 2011.
33. Stonington, S., Holmes, S. M., and PLoS Medicine Editors. Social medicine in the twenty-first century. PLoS Med. 3(10):e445, 2006.
34. Goldberg, D. S. Social justice, health inequalities, and methodological individualism in U.S. health promotion. Public Health Ethics 5:104-115, 2012.
35. Benach, J., et al. A new typology of policies to tackle health inequalities and scenarios of impact based on Roses population approach. J. Epidemiol. Comm. Health. http://jech.bmj.com/content/early/2012/08/16/jech-2011- 200363.long.
36. Capewell, S., and Graham, H. Will cardiovascular disease prevention widen health inequalities PLoS Med. 7(8):e1000320, 2010.
37. Goldberg, D. S. Global health care is not global health: Populations, inequities, and law as a social determinant of health. In The Globalization of Health Care, ed. I. Glenn Cohen. Oxford, New York, 2013.
38. Commission on Social Determinants of Health. Closing the Gap in a Generation: Health Equity Through Action on Social Determinants of Health. World Health Organization, Geneva, 2008.
39. Fairchild, A. L., et al. The EXODUS of public health. What history can tell us about the future. Am. J. Pub. Health 100:54-63, 2010.
40. Petryna, A. When Experiments Travel: Clinical Trials and the Global Search for Human Subjects. Princeton University, Princeton, 2009.
41. Wendler, D., Emanuel, E. J., and Lie, R. K. The standard of care debate: Can research in developing countries be both ethical and responsive to those countries health needs Am. J. Pub. Health 94:923-928, 2004.
42. Bayer, R. The debate over maternal-fetal HIV transmission prevention trials in Africa, Asia, and the Caribbean: Racist exploitation or exploitation of racism Am. J. Pub. Health 88:567-570, 1998.
43. London, A. J. Justice and the human development approach to international research. Hastings Cent. Rep. 35:24-37, 2005.
44. Navarro, V. The world health situation. In Neoliberalism, Globalization, and Inequalities: Consequences for Health and Quality of Life, ed. V. Navarro. Baywood Publishing, Amityville, NY, 2007.
45. Azetsop, J. New directions in African bioethics: Ways of including public health concerns in the bioethics agenda. Dev. World Bioeth. 11:4-15, 2011.
46. Skrabenek, P. The Death of Humane Medicine and the Rise of Coercive Healthism. Social Affairs Unit, London, 1994.
47. Rose, N. Powers of Freedom: Reframing Political Thought. Cambridge University, New York, 1999.
48. Metzl, J., and Kirkland, A. (eds.). Against Health: How Health Became the New Morality. New York University, New York, 2010.
49. Conrad, P. The Medicalization of Society. Johns Hopkins University Press, Baltimore, 2007.
50. Bell, S., and Figert, A. E. Medicalization and pharmaceuticalization at the intersections: Looking backward, sideways and forward. Soc. Sci. Med. 75:775-783, 2012.
51. Goldberg, D. Intervening at the right point in the causal pathways: Law, policy, and the devastating impact of pain across the globe. Ann. Health Law 22(2):198-223, 2013.
52. Rose, G. The Strategy of Preventive Medicine. Oxford University Press, New York, 1992.
53. Puska, P., and Stahl, T. Health in All Policies-The Finnish initiative: Background, principles, and current issues. Ann. Rev. Pub. Health 31:315-328, 2010.